MyoKardia — Corporate Update (May 2020)
20 slides from MyoKardia's corporate update, May 11, 2020
Slide 1: EXPLORER-HCM Topline Data Supplemental Materials
May 11, 2020 Investor Call: EXPLORER-HCM Topline Data Supplemental Materials Exhibit 99.2
Slide 2: Forward-looking statement
forward-looking statement Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
Slide 3: Introduction
introduction Patients on treatment experienced meaningful results: Improvement of symptoms Improvement in functional status Reduction or elimination of LVOT gradient Mavacamten’s safety results were comparable to placebo Mavacamten was well tolerated; primary and all secondary endpoints were met wit
Slide 4: EXPLORER-HCM study design
EXPLORER-HCM study design Multi-national, randomized, double-blind, placebo-controlled 68 clinical sites 13 countries 108 128 patients enrolled from Europe patients enrolled in the U.S. 15 patients enrolled from Israel [Company logo] 4
Slide 5: EXPLORER-HCM baseline characteristics
EXPLORER-HCM baseline characteristics Mavacamten (n=123) Placebo (n=128) Age, mean, years (SD) 58.5 (12.2) 58.5 (11.8) Female sex, n (%) 57 (46.3) 45 (35.2) NYHA Class, n (%) Class II 88 (71.5) 95 (74.2) Class III 35 (28.5) 33 (25.8) Peak VO2, mL/kg/min, mean (SD) 18.9 (4.9) 19.9 (4.9) NT-proBNP, pg
Slide 6: EXPLORER-HCM baseline echo parameters
EXPLORER-HCM baseline echo parameters Mavacamten (n=123) Placebo (n=128) Resting LVOT gradient, mmHg, mean (SD) 51.7 (29.4) 51.1 (31.9) Valsalva LVOT gradient, mmHg, mean (SD) 72.3 (31.7) 73.9 (32.0) Post-exercise LVOT gradient, mmHg, mean (SD) 85.7 (34.3) 84.7 (35.6) LVEF, % (SD) 74.1 (5.8) 74.2 (5
Slide 7: EXPLORER-HCM primary and secondary objectives
EXPLORER-HCM primary and secondary objectives Secondary Efficacy Objectives Post-exercise LVOT gradient Peak VO2 NYHA Class Kansas City Cardiomyopathy Clinical Summary Score (KCCQ-CSS) Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness of Breath Questions (HCMSQ-SoB) Change from baseline to
Slide 8: Statistically significant benefits at-a-glance
statistically significant benefits at-a-glance Mavacamten (n=123) Placebo (n=128) P-value Primary endpoint Composite functional, n (%) 45 (37%) 22 (17%) 0.0005 Secondary endpoints Post-exercise LVOT peak gradient, mmHg, mean (SD) -47.2 (40.3) -10.7 (29.6) <0.0001 Peak VO2, mL/kg/min, mean (SD) 1.4 (
Slide 9: Meaningful improvements in symptoms and functional capacity
meaningful improvements in symptoms and functional capacity peak VO2 Peak VO2 change from baseline to week 30 (n=251) Mavacamten Placebo mL/kg/min mean (SD) 1.4 (3.1) -0.05 (3.0) p=0.0006 NYHA Class change from baseline to week 30 (n=251) Mavacamten Placebo Improvement of ≥1 classes 65% 31% % achiev
Slide 10: LVOT obstruction was reduced or eliminated in a majority of patients
LVOT obstruction was reduced or eliminated in a majority of patients obstruction Post-exercise LVOT peak gradient at week 30 Mavacamten Placebo Below 50mmHg (Threshold for surgery) 74% (n=101) 21% (n=106) Below 30mmHg (Diagnostic criteria for obstruction) 57% (n=113) 7% (n=113) p<0.0001 of patients
Slide 11: Improvements in quality of life measures
Improvements in quality of life measures HCMSQ-SoB score change from baseline to week 30 mean (SD) Mavacamten Placebo -2.82 (2.7) -0.85 (2.4) p<0.0001 KCCQ-CSS change from baseline to week 30 mean (SD) Mavacamten Placebo 13.6 (14.4) 4.2 (13.7) p<0.0001 [Company logo]11
Slide 12: Dosing approach demonstrated favorable results and was well tolerated
Dosing approach demonstrated favorable results in efficacy measures and was well tolerated 2% (5/251) of participants experienced a temporary discontinuation associated with reduced ejection fraction 3 patients on mavacamten and 2 on placebo Following a dose modification, all patients continued and
Slide 13: Mavacamten was well tolerated
251 mavacamten was well tolerated low drop out rate (2%) 3 due to adverse events (2 mavacamten, 1 placebo) 2 withdrew for other reasons (1 mavacamten, 1 placebo) no participants withdrew due to reduced EF or symptoms of heart failure serious adverse events Occurred in 10 (8.1%) participants on mavac
Slide 14: HCM is largely caused by mutations in the sarcomere
HCM is largely caused by mutations in the sarcomere MYOFIBRIL On/active myosin Off/relaxed myosin Muscle fibers are composed of myofibrils, which in turn are composed of bundles of sarcomeres HEART MUSCLE FIBERS Actin thin filament Actin-myosin cross-bridge Myosin thick filament Force-producing myos
Slide 15: HCM is a progressive, debilitating disease
HCM is a progressive, debilitating disease Note: All figures approximate; reflect estimated totals 1. Maron et al, Circulation 1995 | 2. Maron et al, AJC 2016 | 3. Maron et al, Circulation 2006 current treatment options are inadequate and non-specific 100K diagnosed(2) 530K Undiagnosed Increased mor
Slide 16: Obstructive HCM is a disease of hypercontractility
obstructive HCM HCM is a disease of hypercontractility that leads to hypertrophy and impaired relaxation of the left ventricle The heart is working harder, but unable to fill with sufficient blood to meet the body’s needs In obstructive HCM, the thickening of the heart’s walls may block the flow of
Slide 17: Planned next steps on path to registration
planned next steps on path to registration Present detailed EXPLORER-HCM results at an upcoming cardiovascular medical meeting (2H 2020) Pre-NDA meeting with FDA anticipated (Q3 2020) Submit NDA for marketing approval in the US (Q1 2021) Initiate process with EMA to discuss EXPLORER-HCM study data a
Slide 18: Changing the paradigm for pipeline growth
3 2 MYK-224 nHCM & HFpEF (diastolic) HFrEF (systolic) LUS-1 Danicamtiv* gDCM Begin with proof-of-concept validation in a targeted population Apply our precision medicine approach to adjacent patient populations Leverage learnings to the discovery of new molecules and new indications 1 2 3 Mavacamten
Slide 19: Platform strategy for aggressive value creation
today Q2 2020 Platform strategy for aggressive value creation starting with mavacamten and danicamtiv Positive Phase 3 data for mavacamten in obstructive HCM Growing body of data fueling pipeline – new indications (HFpEF) AND new discoveries Global rights to entire portfolio World-class team focused
Slide 20: Questions
Q@MyYOKARDIA Driven by the heart